Literature DB >> 23839618

Neuromuscular effects of sevoflurane in patients with myasthenia gravis.

T Morita1, H Tsukagoshi, D Kurosaki, T Sugaya, D Yoshikawa, H Shimada.   

Abstract

The current study evaluated the neuromuscular responses following administration of sevoflurane in 14 patients with myasthenia gravis (MG) (I-IIb in Osserman's classification) scheduled for thymectomy and in 11 control patients (ASA I-II) who underwent elective surgery. The electromyographic (EMG) response of the abductor digiti minimi was measured following train-of-four (TOF) stimulation of the ulnar nerve every 20 s. After induction of anesthesia with a combination of 3-4 mg·kg(-1) thiopental and 1-2 μg·kg(-1) fentanyl with 66% N2O and oxygen, an inspired concentration of 4% sevoflurane was administered via a face mask for 7 min. Anesthesia was maintained during surgery with 66% N2O in oxygen and with 1 minimum alveolar concentration (MAC) of end-tidal concentration of sevoflurane. The T1 (the amplitude of the first response) values decreased more profoundly in the MG patients than in the control patients at the end of surgery (P<0.05). Following administration of 4% sevoflurane for 7 min, the TOFR (the ratio of the fourth TOF to the first response) values revealed depressions greater than 10% of preinhalation values in 11 of 14 MG patients with a marked individual variation. This attenuated response was followed by a further depression of the TOFR values with increasing time of 1 MAC sevoflurane anesthesia. On the other hand, no notable changes were observed in patients with normal neuromuscular functions. The most significant factor that correlated with the depression of the TOFR values induced by 1 MAC sevoflurane was the anti-AchR antibody titers (P=0.029). Our results indicate that MG patients have an increased neuromuscular sensitivity to sevoflurane.

Entities:  

Year:  1996        PMID: 23839618     DOI: 10.1007/BF02471383

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  19 in total

1.  Tetanic fade and post-tetanic tension in the absence of neuromuscular blocking agents in anesthetized man.

Authors:  A Stanec; J Heyduk; G Stanec; L R Orkin
Journal:  Anesth Analg       Date:  1978 Jan-Feb       Impact factor: 5.108

Review 2.  Neuroimmunology of myasthenia gravis.

Authors:  A Vincent
Journal:  Brain Behav Immun       Date:  1988-12       Impact factor: 7.217

3.  The dependence of pancuronium- and d-tubocurarine-induced neuromuscular blockades on alveolar concentrations of halothane and forane.

Authors:  R D Miller; W L Way; W M Dolan; W C Stevens; E I Eger
Journal:  Anesthesiology       Date:  1972-12       Impact factor: 7.892

4.  Comparative neuromuscular effects of Forane and halothane alone and in combination with d-tubocurarine in man.

Authors:  R D Miller; E I Eger; W L Way; W C Stevens; W M Dolan
Journal:  Anesthesiology       Date:  1971-07       Impact factor: 7.892

5.  Cerebral awakening concentration of sevoflurane and isoflurane predicted during slow and fast alveolar washout.

Authors:  T Katoh; Y Suguro; T Kimura; K Ikeda
Journal:  Anesth Analg       Date:  1993-11       Impact factor: 5.108

Review 6.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

7.  Acetylcholine receptors and end-plate electrophysiology in myasthenia gravis.

Authors:  Y Ito; R Miledi; A Vincent; J Newsom-Davis
Journal:  Brain       Date:  1978-06       Impact factor: 13.501

8.  Halothane-induced variability in the neuromuscular transmission of patients with myasthenia gravis.

Authors:  E Nilsson; M Paloheimo; K Müller; J Heinonen
Journal:  Acta Anaesthesiol Scand       Date:  1989-07       Impact factor: 2.105

9.  Neuromuscular effects of enflurane, alone and combined with d-Tubocurarine, pancuronium, and succinylcholine, in man.

Authors:  R P Fogdall; R D Miller
Journal:  Anesthesiology       Date:  1975-02       Impact factor: 7.892

10.  Vecuronium dose-response and maintenance requirements in patients with myasthenia gravis.

Authors:  E Nilsson; O A Meretoja
Journal:  Anesthesiology       Date:  1990-07       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.